FDA
-
-
-
-
-
-
-
Cyclacel Pharma (CYCC) Reports Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia
-
-
-
-
-
-
-
Cyclacel Pharmaceuticals Reports First Quarter 2021 Financial Results
-
-
-
-
-
-
-
Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors
-
-
-
-
-
-
-
Cyclacel Pharma (CYCC) Reports Update of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Meeting
-
-
-
-
-
-
-
Cyclacel Pharma (CYCC) Reports Selection of Recommended Phase 2 Dose for CYC065
-
-
-
-
-
-
-
Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

